Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 748935, 8 pages
http://dx.doi.org/10.1155/2014/748935
Clinical Study

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks

Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama Prefecture 641-0012, Japan

Received 13 July 2014; Revised 21 September 2014; Accepted 22 September 2014; Published 28 September 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Hideyuki Tamai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology, “Guidelines for the management of hepatitis C virus infection: first edition, May 2012, the Japan Society of Hepatology,” Hepatology Research, vol. 43, no. 1, pp. 1–34, 2013. View at Publisher · View at Google Scholar
  2. H. Kumada, J. Toyota, T. Okanoue, K. Chayama, H. Tsubouchi, and N. Hayashi, “Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan,” Journal of Hepatology, vol. 56, no. 1, pp. 78–84, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, and H. Kumada, “Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C,” Journal of Viral Hepatitis, vol. 19, no. 2, pp. e134–e142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Karino, I. Ozeki, S. Hige et al., “Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C,” Journal of Viral Hepatitis, vol. 21, no. 5, pp. 341–347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Virlogeux, P. Pradat, F. Bailly et al., “Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score,” Journal of Viral Hepatitis, vol. 21, pp. e98–e107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Akuta, F. Suzuki, M. Hirakawa et al., “Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin,” Hepatology, vol. 52, no. 2, pp. 421–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Chayama, C. N. Hayes, H. Abe et al., “IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C,” Journal of Infectious Diseases, vol. 204, no. 1, pp. 84–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Bota, I. Sporea, R. Şirli, A. M. Neghină, A. Popescu, and M. Străin, “Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis,” Clinical Drug Investigation, vol. 33, no. 5, pp. 325–331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. E. Sherman, S. L. Flamm, N. H. Afdhal et al., “Response-guided telaprevir combination treatment for hepatitis C virus infection,” The New England Journal of Medicine, vol. 365, no. 11, pp. 1014–1024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Hara, N. Akuta, F. Suzuki et al., “A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C,” Journal of Medical Virology, vol. 85, no. 10, pp. 1746–1753, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Sezaki, F. Suzuki, T. Hosaka et al., “Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients,” Hepatology Research, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Simmonds, E. C. Holmes, T.-A. Cha et al., “Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region,” Journal of General Virology, vol. 74, part 11, pp. 2391–2399, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Akuta, F. Suzuki, H. Sezaki et al., “Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy,” Intervirology, vol. 48, no. 6, pp. 372–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Hézode, H. Fontaine, C. Dorival et al., “Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890,” Journal of Hepatology, vol. 59, no. 3, pp. 434–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Colombo, I. Fernández, D. Abdurakhmanov et al., “Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C,” Gut, vol. 63, no. 7, pp. 1150–1158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Akuta, F. Suzuki, T. Fukushima et al., “Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1,” Journal of Clinical Microbiology, vol. 51, no. 9, pp. 2862–2868, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Tsubota, N. Shimada, M. Atsukawa et al., “Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b,” Journal of Gastroenterology and Hepatology, vol. 29, no. 1, pp. 144–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Shimada, A. Tsubota, M. Atsukawa et al., “α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype,” Journal of Medical Virology, vol. 86, no. 3, pp. 461–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Shimada, H. Toyoda, A. Tsubota et al., “Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study,” Journal of Gastroenterology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Tamai, N. Shingaki, T. Shiraki et al., “Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation,” Hepatology Research, vol. 41, no. 12, pp. 1137–1144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Tamai, Y. Mori, N. Shingaki et al., “Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load,” Antiviral Therapy, vol. 19, no. 1, pp. 107–115, 2014. View at Publisher · View at Google Scholar · View at Scopus